Changes in keratin expression during metastatic progression of breast cancer: Impact on the detection of circulating tumor cells

Clinical Cancer Research

Volumn 18, Issue 4, 2012, Pages 993-1003

  Joosse, Simon A ^a   Hannemann, Juliane ^a   Spoẗter, Julia ^a   Bauche, Andreas ^a   Andreas, Antje ^a   Mul̈ler, Volkmar ^a   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN; CYTOKERATIN 10; CYTOKERATIN 13; CYTOKERATIN 14; CYTOKERATIN 15; CYTOKERATIN 16; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 2; CYTOKERATIN 4; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; CYTOKERATIN 8; CYTOKERATIN 9; KERATIN; KERATIN 7 ANTIBODY; KERATIN ANTIBODY; KERATIN ANTIBODY AE1; KERATIN ANTIBODY AE3; KERATIN ANTIBODY C11; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CIRCULATING TUMOR CELL; COMPUTER MODEL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOWN REGULATION; EARLY DIAGNOSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; KERATIN-16; KERATINS; LYMPHATIC METASTASIS; NEOPLASTIC CELLS, CIRCULATING; SURVIVAL ANALYSIS;

EID: 84857097186     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2100     Document Type: Article

References (38)

1. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-56. (Pubitemid 38745530)
2. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007;369:1742-57. (Pubitemid 46755391)
3. Molloy T, van 't Veer LJ. Recent advances in metastasis research. Curr Opin Genet Dev 2008;18:35-41. (Pubitemid 351694450)
4. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793-802. (Pubitemid 41215488)
5. Braun S, Auer D, Marth C. The prognostic impact of bone marrow micrometastases in women with breast cancer. Cancer Invest 2009; 27:598-603.
6. Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005;11:3678-85. (Pubitemid 40685584)
7. Nagaiah G, Abraham J. Circulating tumor cells in the management of breast cancer. Clin Breast Cancer 2010;10:209-16.
8. Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, et al. The prognostic significance of tumor cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res 2011;13:R61.
9. Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N, et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010;17:199-204.
10. Gazzaniga P, Naso G, Gradilone A, Cortesi E, Gandini O, Gianni W, et al. Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors. Int J Cancer 2010; 126:2437-47.
11. Giuliano M, Giordano A, Jackson S, Hess KR, De GU, Mego M, et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 2011;13:R67.
12. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008;8:329-40. (Pubitemid 351596394)
13. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000;342:525-33. (Pubitemid 30117892)
14. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res 2007;13:920-8. (Pubitemid 46340368)
15. Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, et al. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999;1:377-88.
16. Jung R, Petersen K, Kruger W, Wolf M, Wagener C, Zander A, et al. Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. Br J Cancer 1999;81:870-3. (Pubitemid 29504699)
17. Radisky DC. Epithelial-mesenchymal transition. J Cell Sci 2005;118: 4325-6.
18. Thiery JP, Sleeman JP. Complex networks orchestrate epithelialmesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-42. (Pubitemid 43278296)
19. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, et al. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 2005;11: 8006-14. (Pubitemid 41698741)
20. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91. (Pubitemid 39095313)
21. Bartek J, Bartkova J, Schneider J, Taylor-Papadimitriou J, Kovarik J, Rejthar A. Expression of monoclonal antibody-defined epitopes of keratin 19 in human tumours and cultured cells. Eur J Cancer Clin Oncol 1986;22:1441-52. (Pubitemid 17228760)
22. Conrad K, Karsten U, Frank KH, Pasternak G. Immunoblotting of monoclonal anti-cytoskeletal antibodies with cytoskeletal extracts of HeLa and MCF-7 cells. Biomed Biochim Acta 1988;47:697-703.
23. Bartkowiak K, Wieczorek M, Buck F, Harder S, Moldenhauer J, Effenberger KE, et al. Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/progenitor cell protein profile. J Proteome Res 2009;8:2004-14.
24. in-silico.net [Internet]. In-Silico Online, statistical tools; [updated 2011 Dec; cited 2012 Jan]. Available from http://in-silico.net/statistics/.
25. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-9.
26. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9. (Pubitemid 40260888)
27. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27. (Pubitemid 44854747)
28. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat 2011;130:449-55.
29. Gradilone A, Raimondi C, Nicolazzo C, Petracca A, Gandini O, Vincenzi B, et al. Circulating tumor cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J Cell Mol Med 2011;15:1066-70.
30. Effenberger KE, Borgen E, Eulenburg CZ, Bartkowiak K, Grosser A, Synnestvedt M, et al. Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern. Breast Cancer Res Treat 2011;125:729-38.
31. Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene 2011;30:127-38.
32. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
33. Prat A, Perou CM. Mammary development meets cancer genomics. Nat Med 2009;15:842-4.
34. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno- Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008;68: 989-97. (Pubitemid 351272216)
35. Groner B, Vafaizadeh V, Brill B, Klemmt P. Stem cells of the breast and cancer therapy. Womens Health (Lond Engl) 2010;6:205-19.
36. Schaller G, Fuchs I, Pritze W, Ebert A, Herbst H, Pantel K, et al. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res 1996;2: 1879-85. (Pubitemid 26384156)
37. Alix-Panabieres C, Vendrell JP, Slijper M, Pelle O, Barbotte E, Mercier G, et al. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res 2009;11:R39.
38. Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W, et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A 2009;106:3970-5.